12 citations
,
October 2013 in “British Journal of Dermatology” The meeting concluded with optimism about increasing research and better management of vitiligo.
1 citations
,
September 2025 in “Journal of Zhejiang University SCIENCE B” Photodynamic therapy successfully treated skin cancer in a 53-year-old woman.
November 2025 in “International Journal of Research in Medical Sciences” Titagen® improves skin, hair, nail health, and reduces osteoarthritis symptoms safely.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
26 citations
,
October 1978 in “JAMA” Minoxidil helps treat severe high blood pressure.
25 citations
,
May 2020 in “Aesthetic Surgery Journal” The regenerative solution, tSVF, is a safe and effective treatment for various conditions like aged skin, scars, wounds, and more, but more research is needed to find the best way to use it.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
January 2024 in “Archives of dermatological research” Both treatments for alopecia areata showed similar modest effectiveness.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
8 citations
,
July 2001 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New treatments for vitiligo show promise but still face challenges, especially for hands and feet.
7 citations
,
July 2020 in “Pigment cell & melanoma research” RT1640 treatment reverses gray hair and promotes hair growth in mice.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
The natural compound VB-1, found in a Chinese herb, can promote hair growth by boosting cell activity in human skin cells.
68 citations
,
March 2018 in “Biomaterials” Tiny needles with valproic acid can effectively regrow hair.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.